ATYR | tickerfilter.com

Fundamental analysis

32%

Profitability 35%

Dept financing 7%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.83%

1 Month

7.03%

3 Months

-3.18%

6 Months

1.06%

1 Year

109.38%

2 Year

71.79%

Key data

Stock price

$3.35

P/E Ratio

0.00

DAY RANGE

$3.29 - $3.47

EPS

-$0.86

52 WEEK RANGE

$1.42 - $4.66

52 WEEK CHANGE

$109.38

MARKET CAP

303.872 M

YIELD

N/A

SHARES OUTSTANDING

75.796 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-01-2025

BETA

0.21

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,143,251

AVERAGE 30 VOLUME

$1,371,235

Company detail

CEO: Sanjay S. Shukla
Region: US
Website: atyrpharma.com
Employees: 53
IPO year: 2008

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.

ATYR - aTYR PHARMA INC